

Publications Relating to Effects of Artemisinin and its Analogs on Cancer (October 26, 2014):

1. Alagbala AA, McRiner AJ, Borstnik K, Labonte T, Chang W, D'Angelo JG, Gary H, Posner GH, Foster BA. Biological Mechanisms of Action of Novel C-10 Non-Acetal Trioxane Dimers in Prostate Cancer Cell Lines. *J Med Chem* 49:7836-7842 (2006)
2. Alcântara DD, Ribeiro HF, Cardoso PC, Araújo TM, Burbano RR, Guimarães AC, Khayat AS, Oliveira Bahia M. In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). *J Appl Toxicol.* 33(2):151-156, 2013.
3. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF- $\kappa$ B activation. *FEBS Lett.* 552(2-3):141-144 (2003).
4. Al-Oqail, M.M., Galal, A.M., Ahmad, M.S., Al-Fishawi, A.M. & El-Ferally, F.S. New bioactive azaartemisinin derivatives. *Molecules* 8, 901-909 (2003).
5. Amewu RK, Chadwick J, Hussain A, Panda S, Rinki R, Janneh O, Ward SA, Miguel C, Burrell-Saward H, Vivas L, O'Neill PM. Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers. *Bioorg Med Chem.* 21(23):7392-7397, 2013.
6. Anfosso, L., Efferth, T., Albini, A. & Pfeffer, U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. *Pharmacogenomics Journal* 6, 269-278 (2006).
7. Aquino I, Tsuboy MS, Marcarini JC, Mantovani MS, Perazzo FF, Maistro EL. Genotoxic evaluation of the antimalarial drugs artemisinin and artesunate in human HepG2 cells and effects on CASP3 and SOD1 gene expressions. *Genet Mol Res.* 12(3):2517-2527, 2013.
8. Ba Q, Zhou N, Duan J, Chen T, Hao M, Yang X, Li J, Yin J, Chu R, Wang H. Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1. *PLoS One.* 7(8):e42703, 2012.
9. Babba M, Janneh O, Maddock H, Hussain A. P664The anti-cancer drug Artemisinin protects against myocardial ischaemia-reperfusion injury via the recruitment of PI3K-AKT-p70S6k cell survival pathway. *Cardiovasc Res.* 2014 Jul 15;103 Suppl 1:S121. doi: 10.1093/cvr/cvu098.89. Epub 2014 Jun 27.
10. Bachmeier B, Fichtner I, Killian PH, Kronski E, Pfeffer U, Efferth T. Development of Resistance towards Artesunate in MDA-MB-231 Human Breast Cancer Cells. *PLoS One.* 6(5):e20550 (2011).
11. Beekman, A.C. et al. Artemisinin-derived sesquiterpene lactones as potential antitumor compounds. Cytotoxic action against bone marrow and tumor cells. *Planta Medica* 64, 615-619 (1998).
12. Beekman, A.C., Woerdenbag, H.J., Kampinga, H.H. & Konings, A.W.T. Cytotoxicity of artemisinin, a dimer of dihydroartemisinin, artemisitene and eupatoriopicrin as evaluated by the MTT and clonogenic assay. *Phytotherapy Research* 10, 140-144 (1996).
13. Beekman AC et al. Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. *J Nat Prod* 60, 325-330 (1997).
14. Beekman, A.C. et al. Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells. *The Journal of Pharmacy and*

- Pharmacology 49, 1254-1258 (1997).
15. Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks and the ATM/ATR damage response in cancer cells. *Mol Cancer Ther.* 2011 Oct 13. [Epub ahead of print]
  16. Berger, T.G. et al. Artesunate in the treatment of metastatic uveal melanoma - first experiences. *Oncology Reports* 14, 1599-1603 (2005).
  17. Blazquez AG, Fernandez-Dolon M, Sanchez-Vicente L, Maestre AD, Gomez-San Miguel AB, Alvarez M, Serrano MA, Jansen H, Efferth T, Marin JJ, Romero MR. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. *Bioorg Med Chem.* 2013 Apr 29. pii: S0968-0896(13)00385-4. doi: 10.1016/j.bmc.2013.04.059. [Epub ahead of print]
  18. Breuer E, Efferth T. Treatment of Iron-Loaded Veterinary Sarcoma by *Artemisia annua*. *Nat Prod Bioprospect.* 4:113-118, 2014.
  19. Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Voza A, Tufano MA. Artemisinin reduces human melanoma cell migration by down-regulating  $\alpha$ V $\beta$ 3 integrin and reducing metalloproteinase 2 production. *Invest New Drugs* 27, 412-418 (2009)
  20. Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO, Luo S. Artesunate induces necrotic cell death in schwannoma cells. *Cell Death Dis.* 2014 Oct 16;5:e1466. doi: 10.1038/cddis.2014.434.
  21. Cabello CM, Lamore SD, Bair WB 3rd, Qiao S, Azimian S, Lesson JL, Wondrak GT. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. *Invest New Drugs.* 2011 May 6. [Epub ahead of print]
  22. Cai HH, Cai J, Yang PH. Electrochemical activity of holotransferrin and its electrocatalysis-mediated process of artemisinin. *Bioorg Med Chem Lett.* 19, 863-866 (2009)
  23. Cai X, You P, Cai J, Yang X, Chen Q, Huang F. ART-induced biophysical and biochemical alterations of Jurkat cell membrane. *Micron.* 2010 Sep 8. [Epub ahead of print]
  24. Cao, P. & Wang, Z. Antitumor activities of artemisinin and its derivatives. *Zhongliu Fangzhi Zazhi* 11, 666-668 (2004).
  25. Chadwick, J., Mercer, A.E., Park, B.K., Cosstick, R. & O'Neill, P.M. Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against *P. falciparum* malaria parasites and HL-60 cancer cells. *Bioorganic & Medicinal Chemistry* 17, 1325-1338 (2009).
  26. Chadwick J, Jones M, Mercer AE, Stocks PA, Ward SA, Park BK, O'Neill PM. Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in *Plasmodium falciparum* and HL-60 cancer cell lines. *Bioorg Med Chem.* 18, 2586-597 (2010).
  27. Chaijaroenkul W, Viyanant V, Mahavorasirikul W, Na-Bangchang K. Cytotoxic Activity of Artemisinin Derivatives Against Cholangiocarcinoma (CL-6) and Hepatocarcinoma (Hep-G2) Cell Lines. *Asian Pac J Cancer Prev.* 12(1):55-59 (2011).
  28. Chan, H.W., Singh, N.P., and Lai, H.C. Cytotoxicity of dihydroartemisinin toward Molt-4 cells attenuated by N-tert-butyl-alpha-phenylnitron and deferoxamine. *Anticancer Research* 33:4389-4393, 2013.

29. Chen, H., Sun, B., Pan, S., Jiang, H. & Sun, X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. *Anti-Cancer Drugs* 20, 131-140 (2009).
30. Chen, H. & Zhou, H. Inhibitory effects of artesunate on angiogenesis. *Yaoxue Xuebao* 39, 29-33 (2004).
31. Chen H, Sun B, Pan SH, Li J, Xue DB, Meng QH, Jiang HC. Study on anticancer effect of dihydroartemisinin on pancreatic cancer. *Zhonghua Wai Ke Za Zhi.* 47(13):1002-1005 (2009).
32. Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X, Xue D Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. *J Cancer Res Clin Oncol.* 136, 897-903 (2010)
33. Chen H, Shi L, Yang X, Li S, Guo X, Pan L. Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. *Int J Hematol.* 2010 Oct 14. [Epub ahead of print]
34. Chen, H.-H., Zhou, H.-J. & Fang, X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. *Pharmacological Research* 48, 231-236 (2003).
35. Chen, H-H., Zhou, H-J., Wang, W.Q. & Wu, G.D. Antimalarial dihydroartemisinin also inhibits angiogenesis. *Cancer Chemther Pharmacol* 53:423-431 (2004)
36. Chen, H.-H., Zhou, H.-J., Wu, G.-D. & Lou, X.-E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. *Pharmacology* 71, 1-9 (2004).
37. Chen J, Guo Z, Wang HB, Zhou JJ, Zhang WJ, Chen QW. Multifunctional mesoporous nanoparticles as pH-responsive Fe(2+) reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth. *Biomaterials.* 35(24):6498-6507, 2014.
38. Chen J, Chen X, Wang F, Gao H, Hu W. Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway. *Neurol Sci.* 2014 Oct 10. [Epub ahead of print]
39. Chen K, Shou LM, Lin F, Duan WM, Wu MY, Xie X, Xie YF, Li W, Tao M. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. *Anticancer Drugs.* 2014 Feb 10. [Epub ahead of print]
40. Chen T et al. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. *J Cell Mol Med.* 13:1358-1370 (2009)
41. Chen, Y., Lin, X., Park, H. & Greever, R. Study of artemisinin nanocapsules as anticancer drug delivery systems. *Nanomedicine.* 2009 Jan 18. [Epub ahead of print]
42. Chen X, Han K, Chen F, Wu C, Huang W. [Effects of Artesunate on the Invasion of Lung Adenocarcinoma A549 Cells and Expression of ICAM-1 and MMP-9]. *Zhongguo Fei Ai Za Zhi.* 16(11):567-571, 2013. [Article in Chinese]
43. Cheng R, Li C, Li C, Wei L, Li L, Zhang Y, Yao Y, Gu X, Cai W, Yang Z, Ma J, Yang X, Gao G. The Artemisinin derivative Artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. *Invest Ophthalmol Vis Sci.* 2013 Apr 23. pii: iovs.12-11068v1. doi: 10.1167/iov.12-11068. [Epub ahead of print]
44. Chikazawa S, Kitahara Y, Ando E, Hori Y, Hoshi F, Kanai K, Ito N, Higuchi S. Erythrophagocytosis Enhances Heme-Dependent Cytotoxicity of Antimalarial Drugs in Canine Histiocytic Sarcoma Cell Line DH82. *J Vet Med Sci.* 2013 Sep 20. [Epub ahead of print]

45. Cho, S., Oh, S., Um, Y., Jung, J.H., Ham, J., Shin, W.S. & Lee, S. Synthesis of 10-substituted triazolyl artemisinins possessing anticancer activity via Huisgen 1,3-dipolar cycloaddition. *Bioorg Med Chem Lett* 19, 382-385 (2009).
46. Cho YC, Lee SH, Lee M, Kim HJ, Oak MH, Lee IS, Kang BY. Enhanced IL-12p40 production in LPS-stimulated macrophages by inhibiting JNK activation by artemisinin. *Arch Pharm Res.* 35(11):1961-1968 (2012).
47. Chung, S.Y. et al. Effect of natural compounds on P-glycoprotein activity in human uterine sarcoma cells. *Yakche Hakhoechi* 35, 249-254 (2005).
48. Chung, S.Y. et al. Inhibition of P-glycoprotein by natural products in human breast cancer cells. *Archives of Pharmacal Research* 28, 823-828 (2005).
49. Copple IM, Mercer AE, Firman J, Donegan G, Herpers B, Wong MH, Chadwick J, Bringela AD, Cristiano ML, Van De Water B, Ward SA, O'Neill PM, Park BK. EXAMINATION OF THE CYTOTOXIC AND EMBRYOTOXIC POTENTIAL, AND UNDERLYING MECHANISMS, OF NEXT-GENERATION SYNTHETIC TRIOXOLANE AND TETRAOXANE ANTIMALARIALS. *Mol Med.* 2012 May 29. doi: 10.2119/molmed.2012.00154. [Epub ahead of print]
50. Crespo-Ortiz MP, Wei MQ Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. *J Biomed Biotechnol.* 2012;2012:247597. Epub 2011 Nov 22.
51. Cui, C. et al. Influence of artesunate and oxymatrine on immunosuppressive effect of mouse colon-rectal carcinoma cell line. *Xiandai Mianyixue* 26, 152-156 (2006).
52. Cvijetić IN, Zizak ZP, Stanojković TP, Juranić ZD, Terzić N, Opsenica IM, Opsenica DM, Juranić IO, Drakulić BJ. An alignment independent 3D QSAR study of the antiproliferative activity of 1,2,4,5-tetraoxanes. *Eur J Med Chem.* 45(10):4570-4577 (2010).
53. Dadgar N, Alavi SE, Esfahani MK, Akbarzadeh A. Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line. *Indian J Clin Biochem.* 28(4):410-412, 2013.
54. Dadgar N, Koohi Moftakhari Esfahani M, Torabi S, Alavi SE, Akbarzadeh A. Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer. *Indian J Clin Biochem.* 29(4):501-504, 2014.
55. D'Alessandro S., Gelati M., Basilico N., Parati E.A., Haynes R.K & Taramelli D. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. *Toxicology* 241, 66-74 (2007).
56. D'Alessandro S, Basilico N, Corbett Y, Scaccabarozzi D, Omodeo-Salè F, Saresella M, Marventano I, Vaillant M, Olliaro P, Taramelli D. Hypoxia modulates the effect of dihydroartemisinin on endothelial cells. *Biochem Pharmacol.* 82(5):476-484 (2011).
57. Das SS, Nanda GG, Alone DP. Artemisinin and Curcumin inhibit *Drosophila* brain tumor, prolong life span, and restore locomotor activity. *IUBMB Life.* 2014 Jun 27. doi: 10.1002/iub.1284. [Epub ahead of print]
58. Dell'Eva, R. et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. *Biochemical Pharmacology* 68, 2359-2366 (2004).
59. Deng, D.A., Xu, C.H. & Cai, J.C. Derivatives of arteannuin B with antileukemia activity. *Acta Pharmaceutica Sinica* 27(4): 317-320 (1992)
60. Deng, X.-R., Yu, H.-P., Wang, K.-Q. & Li, X.-M. Inhibitory effect of artemisinin on

- hepatoma H22 cells. *Shiyong Linchuang Yixue* 8, 1-3, 7 (2007).
61. Disbrow, G.L. et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. *Cancer Research* 65, 10854-10861 (2005).
  62. Du, J.-H., Ma, Z.-J., Li, J.-X. & Zhang, H.-D. An oncosis-like cell death of pancreatic cancer Panc-1 cells induced by artesunate is related to generation of reactive oxygen species. *Zhongguo Aizheng Zazhi* 18, 410-414 (2008).
  63. Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. *Cancer Chemother Pharmacol.* 65(5): 895-902 (2010).
  64. Efferth, T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. *Drug Resistance Updates* 8, 85-97 (2005).
  65. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. *Current Drug Targets* 7, 407-421 (2006).
  66. Efferth, T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. *Planta Medica* 73, 299-309 (2007).
  67. Efferth, T. et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. *Free Radical Biology & Medicine* 37, 998-1009 (2004).
  68. Efferth, T., Briehl, M.M. & Tome, M.E. Role of antioxidant genes for the activity of artesunate against tumor cells. *International Journal of Oncology* 23, 1231-1235 (2003).
  69. Efferth, T. et al. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. *Blood cells, Molecules & Diseases* 28, 160-168 (2002).
  70. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. & Chitambar, C.R. The anti-malarial artesunate is also active against cancer. *International Journal of Oncology* 18, 767-773 (2001).
  71. Efferth, T., Giaisi, M., Merling, A., Kramer Peter, H. & Li-Weber, M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. *PLoS ONE* 2, e693 (2007).
  72. Efferth, T. et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. *Clinical Cancer Research* 14, 2405-2412 (2008).
  73. Efferth, T., Li, P.C.H., Konkimalla, V.S.B. & Kaina, B. From traditional Chinese medicine to traditional cancer therapy. *Trends in Molecular Medicine* 13, 353-361 (2007).
  74. Efferth, T. & Oesch, F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. *Biochemical Pharmacology* 68, 3-10 (2004).
  75. Efferth, T., Olbrich, A. & Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. *Biochemical Pharmacology* 64, 617-623 (2002).
  76. Efferth, T., Ramirez, T., Gebhart, E. & Halatsch, M.-E. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. *Biochemical Pharmacology* 67, 1689-1700 (2004).
  77. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO. Molecular modes of action of artesunate in tumor cell lines. *Molecular Pharmacology* 64, 382-394 (2003).
  78. Efferth, T. & Volm, M. Glutathione-related enzymes contribute to resistance of tumor cells

- and low toxicity in normal organs to artesunate. *In Vivo* 19, 225-232 (2005).
79. Efferth T, Herrmann F, Tahrani A, Wink M. Cytotoxic activity of secondary metabolites derived from *Artemisia annua* L. towards cancer cells in comparison to its designated active constituent artemisinin. *Phytomedicine*. 2011 Aug 8. [Epub ahead of print]
  80. Eichhorn T, Winter D, Büchele B, Dirdjaja N, Frank M, Lehmann WD, Mertens R, Krauth-Siegel RL, Simmet T, Granzin J, Efferth T. Molecular interaction of artemisinin with translationally controlled tumor protein (TCTP) of *Plasmodium falciparum*. *Biochem Pharmacol*. 85(1):38-45, 2013.
  81. Fafowora MV, Atanu F, Sanya O, Olorunsogo OO, Erukainure OL. Effect of oral coadministration of artesunate with ferrous sulfate on rat liver mitochondrial membrane permeability transition. *Drug Chem Toxicol*. 34(3):318-323 (2011).
  82. Fan, Y., Zheng, S. & Zhao, G. Effects of artesunate on anoikis resistance in human breast cancer cell MCF-7. *Zhongguo Bingli Shengli Zazhi* 22, 748-751 (2006).
  83. Farsam V, Hassan ZM, Hosseini AZ, Noori S, Mahdavi M, Ranjbar M. Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4(+) CD25(+) FoxP3(+) T reg cells in vivo. *Int Immunopharmacol*. 11, 1802-1808 (2011).
  84. Ferreira JF, Luthria DL, Sasaki T, Heyerick A. Flavonoids from *Artemisia annua* L. as Antioxidants and Their Potential Synergism with Artemisinin against Malaria and Cancer. *Molecules*. 15(5):3135-3170 (2010).
  85. Eichhorn T, Schloissnig S, Hahn B, Wendler A, Mertens R, Lehmann WD, Krauth-Siegel RL, Efferth T. Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. *Mol Biosyst*. 8:1311-1318 (2012)
  86. Finaurini S, Basilico N, Corbett Y, D'Alessandro S, Parapini S, Olliaro P, Haynes RK, Taramelli D. Dihydroartemisinin inhibits the human erythroid cell differentiation by altering the cell cycle. *Toxicology*. 2012 Jun 5. [Epub ahead of print]
  87. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. *Expert Rev Mol Med*. 11:e32 (2009).
  88. Fujita, T. et al. Human fortilin is a molecular target of dihydroartemisinin. *FEBS Letters* 582, 1055-1060 (2008).
  89. Galal A.M. et al. Deoxyartemisinin derivatives from photooxygenation of anhydrodeoxydihydroartemisinin and their cytotoxic evaluation. *Journal of Natural Products* 65, 184-188 (2002).
  90. Galal, A.M. et al. Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. *Bioorganic & Medicinal Chemistry* 17, 741-751 (2009).
  91. Gao N, Budhraj A, Cheng S, Liu EH, Huang C, Chen J, Yang Z, Chen D, Zhang Z, Shi X. Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. *Apoptosis*. 16:511-523 (2011).
  92. Gao X, Luo Z, Xiang T, Wang K, Li J, Wang P. Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells. *Tumori*. 97(6):771-780 (2011).
  93. Gharib A, Faezizadeh Z, Mesbah-Namin SA, Saravani R. Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. *Daru*. 2014 May 28;22(1):44. [Epub ahead of print]

94. Gong, Y., Gallis, B.M., Goodlett, D.R., Yang, Y., Lu, H., Lacoste, E., Lai, H., Wang, S. and Sasaki, T. Synthesis of transferrin conjugates of artemisinin and artemisinin dimer and their effects on breast cancer cell lines. *Anticancer Research* 33(1):123-132, 2013.
95. Gong XM, Zhang Q, Torossian A, Cao JP, Fu S. Selective radiosensitization of human cervical cancer cells and normal cells by artemisinin through the abrogation of radiation-induced G2 block. *Int J Gynecol Cancer*. 22(5):718-724 (2012).
96. Goodrich SK, Schlegel CR, Wang G, Belinson JL. Use of artemisinin and its derivatives to treat HPV-infected/transformed cells and cervical cancer: a review. *Future Oncol*. 2014 Mar;10(4):647-54. doi: 10.2217/fon.13.228.
97. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? *Drug Discov Today*. 2010 Jun 8. [Epub ahead of print]
98. Gravett AM, Liu WM, Krishna S, Chan WC, Haynes RK, Wilson NL, Dalglish AG. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. *Cancer Chemother Pharmacol*. 67:569-577 (2011).
99. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, Efferth T, Eils R, Brady NR. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. *J Biol Chem*. 286(8):6587-6601 (2011).
100. Handrick R, Ontikatzte T, Bauer KD, Freier F, Rübél A, Dürig J, Belka C, Jendrossek V. Dihydroartemisinin Induces Apoptosis by a Bak-dependent Intrinsic Pathway. *Mol Cancer Ther*. 2010 Jul 27. [Epub ahead of print]
101. He RR, Zhou HJ. Progress in research on the anti-tumor effect of artesunate. *Chin J Integr Med*. 14(4):312-316 (2008).
102. He R, Forman M, Mott BT, Venkatadri R, Posner GH, Arav-Boger R. The Unique and Highly-Selective Anti-Cytomegalovirus Activities of Artemisinin-Derived Dimer Diphenyl Phosphate Stem From Combination of Dimer Unit and a Diphenyl Phosphate Moiety. *Antimicrob Agents Chemother*. 2013 Jun 17. [Epub ahead of print]
103. He R, Mott BT, Rosenthal AS, Genna DT, Posner GH, Arav-Boger R. An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. *PLoS One*. 6(8):e24334 (2011)
104. He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, Zhan Z, Dong X, Sun L, Xu H. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte. *Rheumatol Int*. 2009 Oct 27. [Epub ahead of print]
105. Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. *Pharmacol Ther*. 142(1):126-139, 2014.
106. Hooft van Huijsduijnen R<sup>1</sup>, Guy RK<sup>2</sup>, Chibale K<sup>3</sup>, Haynes RK<sup>4</sup>, Peitz I<sup>5</sup>, Kelter G<sup>5</sup>, Phillips MA<sup>6</sup>, Vennerstrom JL<sup>7</sup>, Yuthavong Y<sup>8</sup>, Wells TN<sup>1</sup>. Anticancer properties of distinct antimalarial drug classes. *PLoS One*. 2013 Dec 31;8(12):e82962.
107. Horwedel C, Tsogoeva SB, Wei S, Efferth T. Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. *J Med Chem*. 53(13):4842-4848 (2010).
108. Hosoya, K. et al. Biological activity of dihydroartemisinin in canine osteosarcoma cells lines. *American Journal of Veterinary Research* 69, 519-526 (2008).

109. Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT. Comparison of High-Dose Intermittent and Low-Dose Continuous Oral Artemisinin in Dogs With Naturally Occurring Tumors. *J Am Anim Hosp Assoc.* 2014 Sep 23. [Epub ahead of print]
110. Hou, J., Wang, D., Zhang, R. & Wang, H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. *Clinical Cancer Research* 14, 5519-5530 (2008).
111. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y, Tang W, Zuo JP. SM934, a water-soluble derivative of artemisinin, exerts immunosuppressive functions in vitro and in vivo. *Int Immunopharmacol.* 9(13-14):1509-1517 (2009).
112. Hou LF, He SJ, Li X, Wan CP, Yang Y, Zhang XH, He PL, Zhou Y, Zhu FH, Yang YF, Li Y, Tang W, Zuo JP. SM934 Treated Lupus-Prone NZB×NZW F(1) Mice by Enhancing Macrophage Interleukin-10 Production and Suppressing Pathogenic T Cell Development. *PLoS One.* 7(2):e32424 (2012).
113. Hu W, Chen SS, Zhang JL, Lou XE, Zhou HJ. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. *Cancer Lett.* 2013 Oct 4. pii: S0304-3835(13)00704-0. doi: 10.1016/j.canlet.2013.09.035. [Epub ahead of print]
114. Hu YQ et al. Apoptosis in human hepatoma cell line SMMC-7721 induced by water-soluble macromolecular components of *Artemisia capillaris* Thunberg. *Japanese Journal of Cancer Research* 91, 113-117 (2000).
115. Hua Y, Xian-Jie T. Research advance in antitumor activities of artemisinin and its derivatives. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.* 35(4):466-471, 2013.
116. Huan-Huan C et al. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. *Cancer Letters* 211,163-173 (2004).
117. Huang C, Ba Q, Yue Q, Li J, Li J, Chu R, Wang H. Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction. *Mol Biosyst.* 2013 Oct 2. [Epub ahead of print]
118. Huang, X.-F., Yuan, D., Zhang, C.-C. & Zhang, X.-P. Artesunate induces human prostate cancer cell line PC-3 differentiation and cell cycle arrest. *Zhongxiyi Jiehe Xuebao* 6, 591-594 (2008).
119. Huang, X.-J. et al. Dihydroartemisinin Potentiates the Cytotoxic Effect of Temozolomide in Rat C6 Glioma Cells. *Pharmacology* 82, 1-9 (2008).
120. Huang, X.-J., Ma, Z.-Q., Zhang, W.-P., Lu, Y.-B. & Wei, E.-Q. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. *Journal of Pharmacy and Pharmacology* 59, 849-856 (2007).
121. Huang Z, Zhang Y, Jiang D, Huang X, Huang B, Luo G. [Apoptosis of nasopharyngeal carcinoma cells line CNE-2 induced by dihydroartemisinin and its possible mechanism]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 27(13):717-720, 2013.[Article in Chinese]
122. Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW, Jeong HG. Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. *Biochem Pharmacol.* 2010 Feb 9. [Epub ahead of print]
123. Jansen, F.H. & Soomro, S.A. Chemical instability determines the biological action of the



- artemisinins. *Current Medicinal Chemistry* 14, 3243-3259 (2007).
124. Jansen FH, Adoubi I, J C KC, DE Cnodder T, Jansen N, Tschulakow A, Efferth T. First study of oral Artemimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. *Anticancer Res.* 31(12):4417-4422 (2011).
  125. Jeyadevan, J.P. et al. Antimalarial and Antitumor Evaluation of Novel C-10 Non-Acetal Dimers of beta -(2-Hydroxyethyl) deoxyartemisinin. *Journal of Medicinal Chemistry* 47, 1290-1298 (2004).
  126. Jia L, Li X. [The role and mechanism of anticancer of dihydroartemisinin]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 27(18):1033-1036, 2013. [Article in Chinese]
  127. Jiang W, Huang Y, Wang JP, Yu XY, Zhang LY. The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo. *Asian Pac J Cancer Prev.* 14(8):4615-4619, 2013.
  128. Jiang Z, Chai J, Chuang HH, Li S, Wang T, Cheng Y, Chen W, Zhou D. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. *Anticancer Drugs.* 23(6): 606-613, 2012.
  129. Jiao, Y. et al. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. *Acta Pharmacologica Sinica* 28, 1045-1056 (2007).
  130. Jones, M., Mercer, A.E., Stocks, P.A., La Pensée, L.J., Cosstick, R., Park, B.K., Kennedy, M.E., Piantanida, I., Ward, S.A., Davies, J., Bray, P.G., Rawe, S.L., Baird, J., Charidza, T., Janneh, O., O'Neill, P.M. Antitumor and antimalarial activity of artemisinin-acridine hybrids. *Bioorganic & Medicinal Chemistry Letters* 19:2033-2037 (2009).
  131. Jung M, Lee S, Ham J, Lee K, Kim H, Kim SK. Antitumor activity of novel deoxyartemisinin monomers, dimers, and trimer. *J Med Chem.* 46:987-994 (2003).
  132. Jung, M., Tak, J., Chung, W.-Y. & Park, K.-K. Antiangiogenic activity of deoxyartemisinin derivatives on chorioallantoic membrane. *Bioorganic & Medicinal Chemistry Letters* 16, 1227-1230 (2006).
  133. Jung M, Park N, Moon HI, Lee Y, Chung WY, Park KK. Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxyartemisinin. *Bioorg Med Chem Lett.* 19(22):6303-6306 (2009)
  134. Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, Debatin KM, Halatsch ME<sup>1</sup>. Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines. *Anticancer Agents Med Chem.* 14(2):313-318, 2014.
  135. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. *PLoS One* 2, e798 (2007).
  136. Kim, S.H., Chun, S.-Y. & Kim, T.S. Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKCalpha /ERK pathway. *European Journal of Pharmacology* 587, 65-72 (2008).
  137. Kim S.H. et al. Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin. *European Journal of Pharmacology* 482, 67-76 (2003).
  138. Kim, S.J. et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. *Journal of Cancer Research and Clinical Oncology* 132, 129-135 (2006).
  139. Kobayashi D, Hirayama M, Komohara Y, Mizuguchi S, Wilson Morifuji M, Ihn H, Takeya M, Kuramochi A, Araki N. Translationally Controlled Tumor Protein is a Novel

- Biological Target for Neurofibromatosis Type 1 (NF1)-associated Tumors. *J Biol Chem.* 2014 Aug 4. pii: jbc.M114.568253. [Epub ahead of print]
140. Kong R, Jia G, Cheng ZX, Wang YW, Mu M, Wang SJ, Pan SH, Gao Y, Jiang HC, Dong DL, Sun B. Dihydroartemisinin Enhances Apo2L/TRAIL-Mediated Apoptosis in Pancreatic Cancer Cells via ROS-Mediated Up-Regulation of Death Receptor 5. *PLoS One.* 7(5):e37222 (2012).
  141. Konkimalla, V.B. et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. *Nitric Oxide* 19, 184-191 (2008).
  142. Konkimalla, V.B., McCubrey James, A. & Efferth, T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. *Current Cancer Drug Targets* 9, 72-80 (2009).
  143. Krishna, S., Bustamante, L., Haynes, R.K. & Staines, H.M. Artemisinins: their growing importance in medicine. *Trends in Pharmacological Sciences* 29, 520-527 (2008).
  144. Krusche B, Arend J, Efferth T. Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo. *Evid Based Complement Alternat Med.* 2013;2013:454783. doi: 10.1155/2013/454783. Epub 2013 Oct 8.
  145. Kumar N, Sharma M, Rawat DS. Medicinal Chemistry Perspectives of Trioxanes and Tetraoxanes. *Curr Med Chem.* 2011 Aug 9. [Epub ahead of print]
  146. Kumar N, Khan SI, Atheaya H, Mamgain R, Rawat DS. Synthesis and in vitro antimalarial activity of tetraoxane-amine/amide conjugates. *Eur J Med Chem.* 46(7):2816-2827 (2011).
  147. La Pensée L, Sabbani S, Sharma R, Bhamra I, Shore E, Chadwick AE, Berry NG, Firman J, Araujo NC, Cabral L, Cristiano ML, Bateman C, Janneh O, Gavrilu A, Wu YH, Hussain A, Ward SA, Stocks PA, Cosstick R, O'Neill PM. Artemisinin-Polypyrrole Conjugates: Synthesis, DNA Binding Studies and Preliminary Antiproliferative Evaluation. *ChemMedChem.* 2013 Mar 11. doi: 10.1002/cmcd.201200536. [Epub ahead of print]
  148. Lai, H. & Singh, N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. *Cancer Letters* 91, 41-46 (1995).
  149. Lai, H., Sasaki, T. & Singh, N.P. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. *Expert Opinion on Therapeutic Targets* 9, 995-1007 (2005).
  150. Lai, H., Sasaki, T., Singh, N.P. & Messay, A. Effects of artemisinin-tagged holotransferrin on cancer cells. *Life Sciences* 76, 1267-1279 (2005).
  151. Lai, H. & Singh, N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. *Cancer Letters* 231, 43-48 (2006).
  152. Lai, H., Nakase I., Lacoste E., Singh N.P. & Sasaki, T. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. *Anticancer Research* 29, 3807-3810 (2009)
  153. Lai, H., Singh, N.P., Sasaki, T. Development of artemisinin compounds for cancer treatment. *Investigational New Drugs* 31, 230-246 (2013).
  154. Langroudi L, Hassan ZM, Ebtakar M, Mahdavi M, Pakravan N, Noori S. A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. *Int Immunopharmacol.* 10:1055-1061 (2010).
  155. Lee, C.-H. et al. NMR studies on novel antitumor drug candidates, deoxyartemisinin and

- carboxypropyldeoxyartemisinin. *Biochemical and Biophysical Research Communications* 274, 359-369 (2000).
156. Lee IS, Ryu DK, Lim J, Cho S, Kang BY, Choi HJ. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. *Neurosci Lett.* 2011 Dec 29. [Epub ahead of print]
  157. Lee J. et al. Dihydroartemisinin down-regulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. *Cancer Chemother Pharmacol* 57, 213-220 (2006).
  158. Lee KP, Park ES, Kim DE, Park IS, Kim JT, Hong H. Artemisinin attenuates platelet-derived growth factor BB-induced migration of vascular smooth muscle cells. *Nutr Res Pract.* 8(5):521-525, 2014.
  159. Li J and Zhou HJ. Dihydroartemisinin inhibits the expression of vascular endothelial growth factor in K562 cells. *Yao Xue Xue Bao* 240, 1041-1045 (2005).
  160. Li, L.-N. et al. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta -catenin pathway. *International Journal of Cancer* 121, 1360-1365 (2007).
  161. Li, L.-N. et al. Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. *European Journal of Pharmacology* 588, 1-8 (2008).
  162. Li, P., Wang, G. & Zhang, Y. Advances in pharmacological action of artesunate. *Jishengchongbing Yu Ganranxingjibing* 6, 109-111 (2008).
  163. Li P, Yang S, Dou M, Chen Y, Zhang J, Zhao X. Synergic effects of artemisinin and resveratrol in cancer cells. *J Cancer Res Clin Oncol.* 2014 Jul 22. [Epub ahead of print]
  164. Li, P.C.H. et al. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. *Cancer Research* 68, 4347-4351 (2008).
  165. Li, S., Pan, L. & Xue, F. Effects of artesunate on myeloma cell line SP2/0 and its mechanism. *Zhonghua Zhongliu Zazhi* 30, 16-20 (2008).
  166. Li, S.-H. & Pan, L. Research advances in antitumor mechanism of artemisinin and its derivatives. *Zhongchengyao* 29, 561-562 (2007).
  167. Li, S.-H., Pan, L. & Xue, F. Strong suppression of SP2/0 myeloma cell proliferation and enhanced apoptosis by artesunate. *Zhongchengyao* 29, 434-435 (2007).
  168. Li T, Chen H, Wei N, Mei X, Zhang S, Liu DL, Gao Y, Bai SF, Liu XG, Zhou YX. Anti-inflammatory and immunomodulatory mechanisms of artemisinin on contact hypersensitivity. *Int Immunopharmacol.* 2011 Nov 26. [Epub ahead of print]
  169. Li W et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. *PLoS Genet* 1(3), e36 (2005).
  170. Li, X., Ling, V. & Li Paul, C.H. Same-single-cell analysis for the study of drug efflux modulation of multidrug resistant cells using a microfluidic chip. *Analytical chemistry* 80, 4095-4102 (2008).
  171. Li Y et al. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. *Bioorg Med Chem Lett* 11, 5-8 (2001).
  172. Li YJ, Zhou JH, Du XX, Jia de X, Wu CL, Huang P, Han Y, Sui H, Wei XL, Liu L, Yuan HH, Zhang TT, Zhang WJ, Xie R, Lang XH, Liu T, Jiang CL, Wang LY, Bai YX. Dihydroartemisinin Accentuates the Anti-Tumor Effects of Photodynamic Therapy via Inactivation of NF- $\kappa$ B in Eca109 and Ec9706 Esophageal Cancer Cells. *Cell Physiol Biochem.* 33(5):1527-1536 (2014).

173. Lin, F., Qian, Z., Xue, H., Ding, J. & Lin, L. Comparison of inhibitory effects between artemisinin and artesunate on proliferation of MCF-7 cells in vitro. *Zhongcaoyao* 34, 347-349 (2003).
174. Liu JJ, Fei AM, Nie RM, Wang J, Li Y, Wang ZY, Mi JQ. [A New Artemisinin Derivative SM1044 Induces Apoptosis of Kasumi-1 Cells and Its Mechanism.] *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 19(3):607-611 (2011). [Article in Chinese]
175. Liu, L., Wang, J., Liu, J., Guo, J. & Zuo, L. Inhibitory effect of artesunate on human esophageal squamous carcinoma and its related mechanism. *Zhongguo Yike Daxue Xuebao* 37, 529-531 (2008).
176. Liu L, Zuo LF, Guo JW. Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. *Oncol Lett*. 6(5):1475-1481, 2013.
177. Liu LK, Wu HF, Guo ZR, Chen XJ, Yang D, Shu YQ, Zhang JN. Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model. *Asian Pac J Cancer Prev*. 15(6):2511-2515, 2014.
178. Liu NF, Qu LB, Xiang BR, Yang R. [Antitumor mechanism of Qinghaosu derivatives--molecular docking studies of Qinghaosu derivatives with transferrin]. [Article in Chinese] *Yao Xue Xue Bao*. 44(2):140-144, 2009.
179. Liu WM, Gravett AM, Dalglish AG. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. *Int J Cancer*. 128(6):1471-1480 (2011).
180. Liu, X. et al. Artesunate reverses immunosuppression of 1929 tumor cells. *Zhongguo Mianyixue Zazhi* 23, 985-988 (2007).
181. Liu, Y., Wong, V.K.-W., Ko, B.C.-B., Wong, M.-K. & Che, C.-M. Synthesis and cytotoxicity studies of artemisinin derivatives containing lipophilic alkyl carbon chains. *Organic Letters* 7, 1561-1564 (2005).
182. Liu Y, Lok CN, Ko BC, Shum TY, Wong MK, Che CM. Subcellular localization of a fluorescent artemisinin derivative to endoplasmic reticulum. *Org Lett*. 12(7):1420-1423 (2010).
183. Liu Y, Cui YF. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines. *Asian Pac J Cancer Prev*. 14(9):5243-5248, 2013.
184. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. *Cancer Lett*. 2010 Aug 2. [Epub ahead of print]
185. Lombard MC, N'da DD, Breytenbach JC, Kolesnikova NI, Ba CT, Wein S, Norman J, Denti P, Vial H, Wiesner L. Antimalarial and Anticancer Activities of Artemisinin-quinoline Hybrid-Dimers and Pharmacokinetic Properties in Mice. *Eur J Pharm Sci*. 2012 Oct 12. pii: S0928-0987(12)00371-5. doi: 10.1016/j.ejps.2012.09.019. [Epub ahead of print]
186. Longxi P, Buwu F, Yuan W, Sinan G. Expression of p53 in the Effects of Artesunate on Induction of Apoptosis and Inhibition of Proliferation in Rat Primary Hepatic Stellate Cells. *PLoS One*. 6(10):e26500 (2011).
187. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. *Cancer Biol Ther*. 7, 1017-1023 (2008)
188. Lu, J.J., Meng, L.H., Shankavaram, U.T., Zhu, C.H., Tong, L.J., Chen, G., Lin, L.P.,

- Weinstein, J.N., & Ding, J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. *Biochem Pharmacol.* 2010 Mar 2. [Epub ahead of print]
189. Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. *Invest New Drugs.* 2010 Jul 7. [Epub ahead of print]
190. Lu JJ, Chen SM, Ding J, Meng LH. Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. *Mol Cell Biochem.* 360(1-2):329-337 (2012).
191. Lu JJ, Yang Z, Lu DZ, Wo XD, Shi JJ, Lin TQ, Wang MM, Li Y, Tang LH. Dihydroartemisinin-induced inhibition of proliferation in BEL-7402 cells: An analysis of the mitochondrial proteome. *Mol Med Report.* 2012 May 8. doi: 10.3892/mmr.2012.906. [Epub ahead of print]
192. Lu M, Sun L, Zhou J, Yang J. Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondria-dependent pathway. *Tumour Biol.* 2014 Feb 12. [Epub ahead of print]
193. Lu P, Yao S, Cai J, Yang PH. Synthesis and synergetic anti-tumor activity evaluation of dihydroartemisinin-organogermanium(IV) compound. *Bioorg Med Chem Lett.* 2014 Sep 28. pii: S0960-894X(14)00991-3. doi: 10.1016/j.bmcl.2014.09.048. [Epub ahead of print]
194. Lu, Y.Y., Chen, T.S., Qu, J.L., Pan, W.L., Sun, L. & Wei, X.B. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. *J Biomed Sci.* 16(1):16 (2009).
195. Lu YY, Chen TS, Wang XP, Li L. Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques. *J Biomed Opt.* 2010a Jul-Aug;15(4):046028.
196. Lu YY, Chen TS, Wang XP, Qu JL, Chen M. The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. *FEBS Lett.* 584(18):4019-4026 (2010b).
197. Luo J, Zhu W, Tang Y, Cao H, Zhou Y, Ji R, Zhou X, Lu Z, Yang H, Zhang S, Cao J. Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. *Radiat Oncol.* 2014 Mar 25;9(1):84. [Epub ahead of print]
198. Ma H, Yao Q, Zhang AM, Lin S, Wang XX, Wu L, Sun JG, Chen ZT. The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. *Molecules.* 16(12):10556-10569, 2011.
199. Ma J, Chen L, Liao R, Xu S, Li M, Xu D, Li W. Effects of artemether and dihydroarteannuin on mouse model of scleroderma. *Zhongguo Zhong Yao Za Zhi.* 34, 204-207 (2009).
200. Mao H, Gu H, Qu X, Sun J, Song B, Gao W, Liu J, Shao Q. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. *Int J Mol Med.* 31(1):213-218, 2013.
201. McCarty, M.F. Turning an 'Achilles' Heel' into an asset - activation of HIF-1-alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage. *Medical Hypotheses* 61, 509-511 (2003).
202. Meng H, Xu K, Xu Y, Luo P, Du F, Huang J, Lu W, Yu J, Liu S, Muir B. Nanocapsules based on mPEGylated artesunate prodrug and its cytotoxicity. *Colloids Surf B*

- Biointerfaces. 115C:164-169, (2013).
203. Meng, Y., Li, Y., Liu, B. & Wu, J. Inhibitory effect of pair of hydrogen artemisinin on HeP-2 cells of throat cancer. *Disi Junyi Daxue Xuebao* 25, 2270-2272 (2004).
  204. Mercer, A.E. et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. *Journal of Biological Chemistry* 282, 9372-9382 (2007).
  205. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. *J Biol Chem.* 286(2):987-996 (2011).
  206. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R, Mayer B, Deubzer H, Witt O, Kreuter J, Doerr HW, Cinatl J, Cinatl J Jr. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. *Biochem Pharmacol.* 2009 Aug 18. [Epub ahead of print]
  207. Min D, Kim M, Ricci J, Jung S, Kim K, Chung WY, Park KK, Jung M. Synthesis and anticancer activity of novel deoxoartemisinin-glycolipid hybrids. *Chem Pharm Bull (Tokyo).* 2014 Mar 7. [Epub ahead of print]
  208. Moore, J.C., Lai, H., Li, J.R., Ren, R.L., McDougall, J.A., Singh, N.P. & Chou, C.K. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. *Cancer Letters* 98, 83-87 (1995).
  209. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. *Anticancer Drugs.* 21:423-432 (2010)
  210. Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH. Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: A structure-activity study. *Bioorg Med Chem.* 2013 Apr 22. doi:p11: S0968-0896(13)00353-2. 10.1016/j.bmc.2013.04.027. [Epub ahead of print]
  211. Mu, D. et al. Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. *Methods and Findings in Experimental and Clinical Pharmacology* 29, 33-38 (2007).
  212. Mu, D. et al. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. *Cancer Chemotherapy and Pharmacology* 61, 639-645 (2008).
  213. Mukanganyama, S., Widersten, M., Naik, Y.S., Mannervik, B. & Hasler, J.A. Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. *International Journal of Cancer* 97, 700-705 (2002).
  214. Nakase, I., Gallis, B., Takatani-Nakase, T., Oh, S., Lacoste E., Singh, N.P., Goodlet, D.R., Tanaka, S., Futaki, S., Lai, H. & Sasaki, T. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. *Cancer Letters* 274, 290-298 (2009).
  215. Nakase, I., Lai, H., Singh, N.P., Sasaki, T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. *International Journal of Pharmaceutics* 354, 28-33 (2008).
  216. Nam, W. et al. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. *Head & Neck* 29, 335-340 (2007).
  217. N'da DD, Lombard MC, Clark JA, Connelly MC, Matheny AL, Sigal M, Guy KR. Antiplasmodial activity and cytotoxicity of 10 $\beta$ -aminoquinolinylethylethers of artemisinin. *Drug Res (Stuttg).* 63(2):104-108, 2013.

218. Nguyen HT, Tran TH, Kim JO, Yong CS, Nguyen CN. Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly-D,L-lactide-co-glycolide (PLGA) nanoparticles. *Arch Pharm Res.* 2014 Jun 27. [Epub ahead of print]
219. Noori S, Naderi GA, Hassan ZM, Habibi Z, Bathaie SZ, Hashemi SM. Immunosuppressive activity of a molecule isolated from *Artemisia annua* on DTH responses compared with cyclosporin A. *Int Immunopharmacol.* 4:1301-1306 (2004).
220. Noori S, Hassan ZM, Rezaei B, Rustaiyan A, Habibi Z, Fallahian F. Artemisinin can inhibit the calmodulin-mediated activation of phosphodiesterase in comparison with Cyclosporin A. *Int Immunopharmacol.* 8:1744-1747 (2008).
221. Noori S, Taghikhani M, Hassan ZM, Allameh A, Mostafaei A. Tehranolide could shift the immune response towards Th1 and modulate the intra-tumor infiltrated T regulatory cells. *Iran J Immunol.* 6(4):216-224, 2009.
222. Noori S, Taghikhani M, Hassan ZM, Allameha A, Mostafaei A. Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo. *Mol Immunol.* 47(7-8):1579-1584, 2010.
223. Noori S, Hassan Z, Taghikhani M, Rezaei B, Habibi Z. Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. *Int Immunopharmacol.* 10, 213-217 (2010).
224. Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. *Cell Immunol.* 271:67-72 (2011).
225. Noori S, Hassan ZM. Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis. *Free Radic Biol Med.* 52(9):1987-1999 (2012).
226. Noori S, Hassan ZM, Farsam V. Artemisinin as a chinese medicine, selectively induces apoptosis in pancreatic tumor cell line. *Chin J Integr Med.* 2013 Jun 15. [Epub ahead of print]
227. Noori S, Hassan ZM. Tehranolide inhibits cell proliferation via calmodulin inhibition, PDE, and PKA activation. *Tumour Biol.* 2013 Nov 13. [Epub ahead of print]
228. Oh S, Jeong IH, Shin WS, Lee S. Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells. *Bioorganic & Medicinal Chemistry Letters* 13, 3665-3668 (2003).
229. Oh S, Jeong IH, Ahn CM, Shin WS, Lee S. Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. *Bioorg Med Chem.* 12, 3783-3790 (2004).
230. Oh S, Jeong IH, Shin WS, Lee S. Synthesis and antiangiogenic activity of exo-olefinated deoxyartemisinin derivatives. *Bioorg Med Chem Lett.* 14(14):3683-3686 (2004).
231. Oh S, Shin WS, Ham J, Lee S. Acid-catalyzed synthesis of 10-substituted triazolyl artemisinins and their growth inhibitory activity against various cancer cells. *Bioorg Med Chem Lett.* 20(14), 4112-4115 (2010)
232. Oh, S., Kim, B.J., Singh, N.P., Lai, H. & Sasaki, T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. *Cancer Letters* 274, 33-39 (2009).
233. Ontikatze T, Rudner J, Handrick R, Belka C, Jendrossek V. Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells. *Front Oncol.* 2014 May 19;4:116. doi: 10.3389/fonc.2014.00116. eCollection 2014.
234. Opsenica, D., Kyle, D.E., Milhous, W.K. & Solaja, B.A. Antimalarial, antimycobacterial and antiproliferative activity of phenyl substituted mixed tetraoxanes. *Journal of the*

- Serbian Chemical Society 68, 291-302 (2003).
235. Opsenica, D. et al. Cholic Acid Derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity. *Journal of Medicinal Chemistry* 43, 3274-3282 (2000).
236. Paik, I.-H. et al. Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. *Journal of Medicinal Chemistry* 49, 2731-2734 (2006).
237. Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C. Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. *Oncotarget*. 2014 Mar 24. [Epub ahead of print]
238. Park, J., Lai, H.C., Singh, M., Sasaki, T., and Singh, N.P. Development of a dihydroartemisinin-resistant Molt-4 leukemia cell line. *Anticancer Research* (2014, In press)
239. Park KH, Yoon YD, Han SB, Oh SJ, Yun J, Lee CW, Lee K, Park SK, Kim HM, Kang JS. Artemisinin inhibits lipopolysaccharide-induced interferon- $\beta$  production in RAW 264.7 cells: Implications on signal transducer and activator of transcription-1 signaling and nitric oxide production. *Int Immunopharmacol*. 2012 Oct 2. pii: S1567-5769(12)00283-4. doi: 10.1016/j.intimp.2012.09.012. [Epub ahead of print]
240. Payne Anthony, G. Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis. *Medical Hypotheses* 61, 206-209 (2003).
241. Posner G. H. et al. New chemical and biological aspects of artemisinin-derived trioxane dimers. *Bioorganic & medicinal chemistry* 10, 227-232 (2002).
242. Posner, G.H. et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. *Journal of Medicinal Chemistry* 47, 1299-1301 (2004).
243. Posner, G.H. et al. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. *Journal of Medicinal Chemistry* 46, 1060-1065 (2003).
244. Posner, G.H. et al. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. *Journal of Medicinal Chemistry* 42, 4275-4280 (1999).
245. Potawale, S.E. et al. Research and medicinal potential of *Artemisia annua*: a review. *Pharmacology Online*, 220-235 (2008).
246. Qaderi A, Dadgar N, Mansouri H, Alavi SE, Esfahani MK, Akbarzadeh A. Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks. *Springerplus*. 2:340, 2013.
247. Quetin-Leclercq, J. Potential anticancer and antiparasitic indole alkaloids. *Journal de Pharmacie de Belgique* 49, 181-192 (1994).
248. Raghavamenon AC, Muiyiwa AF, Davis LK, Uppu RM. Dihydroartemisinin induces caspase-8-dependent apoptosis in murine GT1-7 hypothalamic neurons. *Toxicol Mech Methods*. 2011 Feb 10. [Epub ahead of print]
249. Ramacher M, Umansky V, Efferth T. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. *Anticancer Drugs*. 20,910-917 (2009).
250. Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the anti-malarial drug Artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. *Int J Cancer*. 127: 1475-1485 (2010).



251. Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rödel C, Rödel F. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. *Radiother Oncol.* 103(3):394-401 (2012).
252. Reiter C, Herrmann A, Capci A, Efferth T, Tsogoeva SB. New artesunic acid homodimers: Potent reversal agents of multidrug resistance in leukemia cells. *Bioorg Med Chem.* 20: 5637-5641, 2012.
253. Reiter C, Capci Karagöz A, Fröhlich T, Klein V, Zeino M, Viertel K, Held J, Mordmüller B, Emirdağ Öztürk S, Anıl H, Efferth T, Tsogoeva SB. Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against *Plasmodium falciparum* and multidrug-resistant human leukemia cells. *Eur J Med Chem.* 75C:403-412, 2014.
254. Ren YR. [In vitro antitumor activities and mechanisms of galactosylated artemisinin]. *Zhong Yao Cai.* 35(7):1116-1120, (2012). [Article in Chinese]
255. Reungpatthanaphong, P. & Mankhetkorn, S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. *Biological & Pharmaceutical Bulletin* 25, 1555-1561 (2002).
256. Ricci J, Park J, Chung WY, Park KK, Jung M. Concise synthesis and antiangiogenic activity of artemisinin-glycolipid hybrids on chorioallantoic membranes. *Bioorg Med Chem Lett.* 2010 Aug 10. [Epub ahead of print]
257. Ricci J, Kim M, Chung WY, Park KK, Jung M. Discovery of Artemisinin-Glycolipid Hybrids as Anti-oral Cancer Agents. *Chem Pharm Bull (Tokyo).* 59(12):1471-1475 (2011).
258. Riganti, C., Doublier, S., Viarisio, D., Miraglia, E., Pescarmona, G., Ghigo, D., Bosia, A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1 $\alpha$  and P-glycoprotein overexpression. *British Journal of Pharmacology* 156(7):1054-1066 (2009).
259. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. *Mol Pharmacol.* 74(2):476-484 (2008).
260. Righeschi C<sup>1</sup>, Coronello M<sup>2</sup>, Mastrantoni A<sup>3</sup>, Isacchi B<sup>3</sup>, Bergonzi MC<sup>3</sup>, Mini E<sup>2</sup>, Bilia AR<sup>3</sup> Strategy to provide a useful solution to effective delivery of dihydroartemisinin: Development, characterization and in vitro studies of liposomal formulations. *Colloids Surf B Biointerfaces.* 2014 Jan 6;116C:121-127. doi: 10.1016/j.colsurfb.2013.12.019. [Epub ahead of print]
261. Rinner, B. et al. Activity of novel plant extracts against medullary thyroid carcinoma cells. *Anticancer Research* 24, 495-500 (2004).
262. Rosenthal, A.S. et al. Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. *Journal of Medicinal Chemistry* 52, 1198-1203 (2009).
263. Sadava, D., Phillips, T., Lin, C. & Kane, S.E. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. *Cancer Letters* 179, 151-156 (2002).
264. Schnepf N, Corvo J, Pors MJ, Mazon MC. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. *Antiviral Res.* 89(2):186-188 (2011).
265. Sen R, Saha P, Sarkar A, Ganguly S, Chatterjee M. Iron enhances generation of free

- radicals by Artemisinin causing a caspase-independent, apoptotic death in *Leishmania donovani* promastigotes. *Free Radic Res.* 44(11):1289-1295 (2010)
266. Sertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. *Chem Biol Interact.* 185(1):42-52 (2010).
267. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. *Molecules.* 15(4):2886-2910, 2010.
268. Shahbazfar AA, Zare P, Mohammadpour H, Tayefi-Nasrabadi H. Effects of different concentrations of artemisinin and artemisinin-iron combination treatment on Madin Darby Canine Kidney (MDCK) cells. *Interdiscip Toxicol.* 5(1):30-37, 2012.
269. Sieber, S., Gdynia, G., Roth, W., Bonavida, B. & Efferth, T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. *Int J Oncol.* 35, 149-58 (2009).
270. Singh, N.P. & Lai, H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. *Life Sciences* 70, 49-56 (2001).
271. Singh, N.P. & Verma, K.B. Case report of a laryngeal squamous cell carcinoma treated with artesunate. *Arch Oncol* 10, 279-280 (2002).
272. Singh, N.P. & Lai, H.C. Artemisinin induces apoptosis in human cancer cells. *Anticancer Research* 24, 2277-2280 (2004).
273. Singh, N.P. & Lai, H.C. Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. *Anticancer Research* 25, 4325-4331 (2005).
274. Singh N P. & Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. *Integrative Cancer Therapies* 5, 391-394 (2006).
275. Singh NP, Ferreira JF, Park JS, Lai HC. Cytotoxicity of Ethanolic Extracts of *Artemisia annua* to Molt-4 Human Leukemia Cells. *Planta Med.* 77:1788-1793 (2011)
276. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, Wang S, Sasaki T. Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. *Anticancer Research* 31:4111-4114 (2011).
277. Slade D, Galal AM, Gul W, Radwan MM, Ahmed SA, Khan SI, Tekwani BL, Jacob MR, Ross SA, Elsohly MA. Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers. *Bioorg Med Chem.* 17(23):7949-7957 (2009).
278. Sohn, T.A., Bansal, R., Su, G.H., Murphy, K.M. & Kern, S.E. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated. *Carcinogenesis* 23, 949-957 (2002).
279. Soomro S, Konkimalla VB, Langenberg T, Mahringer A, Horwedel C, Holenya P, Brand A, Catin C, Fricker G, Dewerchin M, Carmeliet P, Conway EM, Jansen H, Efferth T. Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. *J Cell Mol Med.* 15: 1122-1135 (2011).
280. Souza MC, Paixão FH, Ferraris FK, Ribeiro I, Henriques Md. Artesunate Exerts a Direct Effect on Endothelial Cell Activation and NF- $\kappa$ B Translocation in a Mechanism Independent of Plasmodium Killing. *Malar Res Treat.* 2012;2012:679090. doi: 10.1155/2012/679090. Epub 2012 Oct 11.
281. Steinbrück L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and g2/m cell

- cycle progression of tumour cells and budding yeast. *Cancer Genomics Proteomics*. 7(6):337-346 (2010).
282. Stockwin, L.H., Han, B., Yu, S.X., Hollingshead, M.G., Elsohly, M.A., Gul, W., Slade, D., Galal, A.M. & Newton, D.L. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. *Int J Cancer*. 125, 1266-1275 (2009).
283. Suberu JO, Romero-Canelón I, Sullu van N, Lapkin AA, Barker GC. Comparative Cytotoxicity of Artemisinin and Cisplatin and Their Interactions with Chlorogenic Acids in MCF7 Breast Cancer Cells. *ChemMedChem*. 2014 Sep 10. doi: 10.1002/cmdc.201402285. [Epub ahead of print]
284. Sun H, Meng X, Han J, Zhang Z, Wang B, Bai X, Zhang X. Anti-cancer activity of DHA on gastric cancer-an in vitro and in vivo study. *Tumour Biol*. 2013 Aug 2. [Epub ahead of print]
285. Sun Q, Teong B, Chen IF, Chang SJ, Gao J, Kuo SM. Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells. *J Biomed Mater Res B Appl Biomater*. 2013 Sep 11. doi: 10.1002/jbm.b.33023. [Epub ahead of print]
286. Sun, W., Han, J., Yang, W., Deng, D. & Yue, X. Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. *Zhongguo Yaoli Xuebao* 13, 541-543 (1992).
287. Sundar, S.N., Marconett, C.N., Doan, V.B., Willoughby, J.A., Sr. & Firestone, G.L. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. *Carcinogenesis* 29, 2252-2258 (2008).
288. Tan SS, Ong B, Cheng C, Ho WE, Tam JK, Stewart AG, Harris T, Wong WS, Tran T. Anti-Malarial Drug Artesunate Inhibits Primary Human Cultured Airway Smooth Muscle Cell Proliferation. *Am J Respir Cell Mol Biol*. 2013 Sep 25. [Epub ahead of print]
289. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, Guo J, Chen X, Wang Y. Anti-cancer natural products isolated from Chinese medicinal herbs. *Chin Med*. 6(1):27 (2011).
290. Tan WQ, Chen G, Jia B, Ye M. Artemisinin inhibits neuroblastoma proliferation through activation of AHP-activated protein kinase (AMPK) signaling. *Pharmazie*. 69(6):468-472 (2014).
291. Tan, X., Plouet, J., Lang, J., Wu, M. & Shen, K. Effects of dihydroartemisinin on proliferation and phosphorylation of mitogen-activated protein kinase in epithelial ovarian cancer cell lines. *Zhonghua Fuchanke Zazhi* 43, 662-665 (2008).
292. Tan XJ, Lang JH, Plouet J, Wu M, Shen K. [Effects of dihydroartemisinin on the adhesion, migration, and invasion of epithelial ovarian cancer cells]. *Zhonghua Yi Xue Za Zhi*. 88(37):2642-2646 (2008).
293. Takatani-Nakase T. Artemisinin: a natural product for fighting against cancer. *Nihon Yakurigaku Zasshi*. 143(2):61-64, 2014.
294. Terzić N, Opsenica D, Milić D, Tinant B, Smith KS, Milhous WK, Solaja BA. Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). *J Med Chem*. 50(21):5118-5127 (2007)
295. Thanaketaisarn O, Waiwut P, Sakurai H, Saiki I. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. *Int J Oncol*. 39(1):279-285 (2011).

296. Tilaoui M, Mouse HA, Jaafari A, Ziyad A. Differential Effect of Artemisinin Against Cancer Cell Lines. *Nat Prod Bioprospect.* 4:189-196, 2014.
297. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. *Anticancer Drugs.* 2011 Dec 17. [Epub ahead of print]
298. Tran KQ, Tin AS, Firestone GL. Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor- $\kappa$ B transcriptional signaling. *Anticancer Drugs.* 2013 Nov 27. [Epub ahead of print]
299. Utzinger, J., Xiao, S.-H., Tanner, M. & Keiser, J. Artemisinins for schistosomiasis and beyond. *Current Opinion in Investigational Drugs* 8, 105-116 (2007).
300. Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens A, Verhelst X, Van Steenkiste C, Libbrecht L, Lambrecht BN, Janssens S, Van Vlierberghe H. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. *Eur J Gastroenterol Hepatol.* 26(8):861-870, 2014.
301. Vieira JB<sup>1</sup>, Braga FS<sup>2</sup>, Lobato CC<sup>3</sup>, Santos CF<sup>4</sup>, Costa JS<sup>5</sup>, Bittencourt JA<sup>6</sup>, Brasil DS<sup>7</sup>, Silva JO<sup>8</sup>, Hage-Melim LP<sup>9</sup>, Macêdo WJ<sup>10</sup>, Carvalho JC<sup>8</sup>, Santos CB<sup>11</sup>. A QSAR, pharmacokinetic and toxicological study of new artemisinin compounds with anticancer activity. *Molecules.* 19(8):10670-10897, 2014.
302. Wang HY, Huang RP, Han P, Xue DB, Li HB, Liu B, Shan P, Wang QS, Li KS, Li HL. The effects of artemisinin on the proliferation and apoptosis of vascular smooth muscle cells of rats. *Cell Biochem Funct.* 2013 Sep 17. doi: 10.1002/cbf.2995. [Epub ahead of print]
303. Wang, J., Guo, Y. & Chen, Z. Anti-tumor effect of artemisinin and its derivants. *Yiyao Daobao* 25, 1042-1044 (2006).
304. Wang, J. et al. The inhibitory effect of artesunate on human esophageal carcinoma associated with modulation of CDC25A and TGFbeta. *Zhongliu* 27, 272-276 (2007).
305. Wang, J. et al. Inhibitory effect of artesunate on human esophageal carcinoma associated with CDC25A modulation. *Di-San Junyi Daxue Xuebao* 29, 428-431 (2007).
306. Wang, J. et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. *Pharmacology* 82, 148-155 (2008).
307. Wang J et al. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. *Pharmacology* 80, 207-218 (2007).
308. Wang JX et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. *British Journal of Pharmacology* 150, 652-661 (2007).
309. Wang JX et al. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. *European Journal of Pharmacology* 564, 211-218 (2007).
310. Wang JX, Tang W, Zhou R, Wan J, Shi LP, Zhang Y, Yang YF, Li Y, Zuo JP. The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses. *Br J Pharmacol.* 153(6):1303-1310, 2008.
311. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM905, an artemisinin derivative,

- inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. *Acta Pharmacol Sin.*30(10):1428-1435, 2009.
312. Wang, L., Zhang, Y. & Sun, W. Influence of compatibility of artemisinin and mitomycin sera on proliferation of sarcoma A549 in vitro. *Zhongguo Yaoye* 17, 8-9 (2008).
313. Wang L, Chen T, Qu J, Wei X. Quantitative analysis of caspase-3 activation by fitting fluorescence emission spectra in living cells. *Micron*. 2009 Jul 23. [Epub ahead of print]
314. Wang, Q., Wu, L., Li, A., Zhao, Y. & Wang, N. Antitumor effect of artesunate on liver cancer. *Zhongguo Zhongyao Zazhi* 26, 707-708, 720 (2001).
315. Wang, Q., Wu, L., Zhao, Y., Zhang, X. & Wang, N. Anticancer effect of artesunate and its mechanism. *Yaoxue Xuebao* 37, 477-478 (2002).
316. Wang S, Sasaki T. Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells. *Bioorg Med Chem Lett*. 23(15):4424-4427, 2013.
317. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW, Sun B. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. *Cancer Lett*. 293(1), 99-108 (2010).
318. Wang SJ, Sun B, Pan SH, Chen H, Kong R, Li J, Xue DB, Bai XW, Jiang HC. Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer. *Zhonghua Wai Ke Za Zhi*. 48(7), 530-534 (2010).
319. Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Chen H, Jiang HC, Pan SH, Xue DB, Bai XW. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF- $\kappa$ B pathway. *Cancer Chemother Pharmacol*. 68(6):1421-1430 (2011)
320. Wang, W., Zhou, H. & Wang, M. Inhibition of artesunate on angiogenesis of decidualoma and marrow in pseudopregnant rats. *Zhongguo Linchuang Yaoxue Zazhi* 14, 375-377 (2005).
321. Wang, Y., Zhu, K., Cui, X., Huang, J. & Song, X. Induction of apoptosis of human lung adenocarcinoma A549 cells by artesunate. *Zhonghua Shiyian Waikexue Zazhi* 24, 121-122 (2007).
322. Wang Y, Huang Z, Wang L, Meng S, Fan Y, Chen T, Cao J, Jiang R, Wang C. The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF- $\kappa$ B canonical signaling pathway in PMA-induced THP-1 monocytes. *Int J Mol Med*. 27(2):233-241 (2011).
323. Wang Y, Yang J, Chen L, Wang J, Wang Y, Luo J, Pan L, Zhang X. Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells. *Chem Biol Interact*. 2014 Apr 2. pii: S0009-2797(14)00114-8. doi: 10.1016/j.cbi.2014.03.011. [Epub ahead of print]
324. Wang, Z., Zhou, H.J., Li, A. & Zhang, J.L. The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells. *Leukemia Research* 2009 Feb 18. [Epub ahead of print]
325. Wang Z, Yu Y, Ma J, Zhang H, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. *Mol Pharm*. 9(9):2646-2657 (2012)
326. Wartenberg M et al. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. *Lab Invest* 83, 1647-1655 (2003).

327. Weifeng T, Feng S, Xiangji L, Changqing S, Zhiquan Q, Huazhong Z, Peining Y, Yong Y, Mengchao W, Xiaoqing J, Wan-Yee L. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. *Phytomedicine*. 18:158-162 (2011).
328. Wickerath M, Singh NP. Additive cytotoxic effects of dihydroartemisinin and sodium salicylate on cancer cells. *Anticancer Res*. 34(7):3399-3401, 2014.
329. Willoughby, J.A. et al. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. *Journal of Biological Chemistry* 284, 2203-2213 (2009).
330. Woerdenbag, H.J. et al. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. *Journal of Natural Products* 56, 849-856 (1993).
331. Wu B, Hu K, Li S, Zhu J, Gu L, Shen H, Hambly BD, Bao S, Di W. Dihydroartemisinin inhibits the growth and metastasis of epithelial ovarian cancer. *Oncol Rep*. 27(1):101-108 (2012).
332. Wu J, Hu D, Yang G, Zhou J, Yang C, Gao Y, Zhu Z. Down-regulation of BMI-1 cooperates with Artemisinin on growth inhibition of nasopharyngeal carcinoma cells. *J Cell Biochem*. 112(7):1938-1948 (2011).
333. Wu, J.M. et al. Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. *European Journal of Medicinal Chemistry* 36, 469-479 (2001).
334. Wu XH et al. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. *Anticancer Drug* 17, 839-848 (2006).
335. Wu XL, Zhang WG, Shi XM, An P, Sun WS, Qiao CL, Wang Z. [Effects of artemisinin on proliferation, apoptosis and Caspase-3 expression of rat mesangial cell] *Zhong Yao Cai*. 33(3):407-410, 2010. [Article in Chinese]
336. Wu ZP et al. Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. *Integrative Cancer Therapy* 8, 88-92 (2009).
337. Xiao F, Gao W, Wang X, Chen T. Amplification activation loop between caspase-8 and -9 dominates artemisinin-induced apoptosis of ASTC-a-1 cells. *Apoptosis*. 2012 Mar 21. [Epub ahead of print]
338. Xie, B. & Ling, J. Advances in anticancer efficacy of artemisinin and its derivatives. *Guangzhou Zhongyiyao Daxue Xuebao* 22, 75-77 (2005).
339. Xie W-L, Yang P-H, Zeng X, Cai J-Y. Effect of 4-(12-dihydroartemisininoxy) benzoic acid hydrazide transferrin tagged drug on human breast cancer cells. *Chin J Anal Chem* 37, 671-675 (2009).
340. Xie WL, Yang PH, Zeng X, Wang H Cai HH, Cai JY. Visual characterization of targeted effect of holo-transferrin-tagged dihydroartemisinin on human breast cancer cells. *Chinese Biology Bulletin* 55, 2390-2395 (2010).
341. Xie L, Zhai X, Ren L, Meng H, Liu C, Zhu W, Zhao Y. Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach. *Chem Pharm Bull (Tokyo)*. 59(8):984-990 (2011).
342. Xie L, Zhai X, Liu C, Li P, Li Y, Guo G, Gong P. Anti-tumor activity of new artemisinin-chalcone hybrids. *Arch Pharm (Weinheim)*. 344(10):639-647 (2011).
343. Xie L, Zhao Y, Zhai X, Li P, Liu C, Li Y, Gong P. The application of tandem aza-wittig

- reaction to synthesize artemisinin-guanidine hybrids and their anti-tumor activity. *Arch Pharm (Weinheim)*. 344(10):631-638 (2011).
344. Xu H et al. Anti-malarial agent artesunate inhibits TNF- $\alpha$ -induced production of proinflammatory cytokines via inhibition of NF- $\kappa$ B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. *Rheumatology* 46, 920-926 (2007).
345. Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, Ye ZM, Li WX. Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. *J Zhejiang Univ Sci B*. 12(4):247-255 (2011).
346. Yamachika, E., Habte, T. & Oda, D. Artemisinin: An alternative treatment for oral squamous cell carcinoma. *Anticancer Research* 24, 2153-2160 (2004).
347. Yang, L., Wu, B. & Dai, B. Effect of Qing Hao Su on the frequency of micronucleus of mouse bone marrow polychromatic erythrocytes. *Zhongyao Tongbao* 9, 132-134 (1984).
348. Yang X, Wang W, Tan J, Song D, Li M, Liu D, Jing Y, Zhao L. Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells. *Bioorg Med Chem Lett*. 19(15):4385-4388, 2009.
349. Yang Y, Zhang X, Wang X, Zhao X, Ren T, Wang F, Yu B. Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin. *Int J Pharm*. 467(1-2):113-122, 2014.
350. Yang Z, Ding J, Yang C, Gao Y, Li X, Chen X, Peng Y, Fang J, Xiao S. Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis. *Curr Med Chem*. 2012 Jul 25. [Epub ahead of print]
351. Yao, L., Xie, H., Jin, Q.-Y., Hu, W.-L. & Chen, L.-J. Analyzing anti-cancer action mechanisms of dihydroartemisinin using gene chip. *Zhongguo Zhong Yao Za Zhi* 33, 1583-1586 (2008).
352. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. *Biochem Pharmacol*. 78:273-283 (2009)
353. Yu WY, Kan WJ, Yu PX, Li MM, Song JS, Zhao F. [Anti-inflammatory effect and mechanism of artemisinin and dihydroartemisinin]. *Zhongguo Zhong Yao Za Zhi*. 37(17):2618-2621 (2012). [Article in Chinese]
354. Yu Z, Wang B, Sui J, Feng Y, Zheng C. A new probe for targeting drug delivery system. *Med Hypotheses*. 72(1):43-44, 2009.
355. Yuan, D. & Zhang, C. Effect of artesunate on prostate cancer cell line PC-3. *Zhongguo Yiyuan Yaoxue Zazhi* 27, 1049-1051 (2007).
356. Zeng QP, Zhang PZ. Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. *Nitric Oxide*. 24(2): 110-112 (2011).
357. Zhang, C.-C., Zhang, X.-P., Yuan, D. & Xiong, Z.-G. Induction of apoptosis in human prostate cancer PC-3 cells by artesunate. *Guangdong Yixue* 29, 374-376 (2008).
358. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. *Biochem Pharmacol*. 2012 Feb 9. [Epub ahead of print]
359. Zhang HT, Wang YL, Zhang J, Zhang QX. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. *Tumour Biol*. 2013 Sep 28. [Epub ahead of print]
360. Zhang JL, Wang Z, Hu W, Chen SS, Lou XE, Zhou HJ. DHA regulates angiogenesis and

- improves the efficiency of CDDP for the treatment of lung carcinoma. *Microvasc Res.* 2013 Mar 1. pii: S0026-2862(13)00026-5. doi: 10.1016/j.mvr.2013.02.006. [Epub ahead of print]
361. Zhang LX, Liu ZN, Ye J, Sha M, Qian H, Bu XH, Luan ZY, Xu XL, Huang AH, Yuan DL, Wu YQ, Wang XX, Wang J, Huang JX, Ye LH. Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. *Cell Biol Int.* 38(5):639-646, 2014.
362. Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. *PLoS One.* 4(10):e7472 (2009).
363. Zhang S, Chen H, Gerhard GS. Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. *Chem Biol Interact.* 186, 30-35 (2010).
364. Zhang S, Ma Y, Jiang J, Dai Z, Gao X, Yin X, Xi W, Min W. Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells. *Oncol Lett.* 7(5):1375-1380, 2014.
365. Zhang, X., Yang, X. & Pan, Q. Antitumor effect and apoptosis induction in human liver cancer cell line (BEL-7402) by sodium artesunate. *Zhongcaoyao* 29, 467-469 (1998).
366. Zhang YJ, Gallis B, Taya M, Wang S, Ho RJ, Sasaki T. pH-Responsive Artemisinin Derivatives and Lipid Nanoparticle Formulations Inhibit Growth of Breast Cancer Cells In Vitro and Induce Down-Regulation of HER Family Members. *PLoS One.* 8(3):e59086 (2013).
367. Zhang, Z. Progress in anti-angiogenesis drugs to lung cancer. *Zhongguo Feiai Zazhi* 9, 96-99 (2006).
368. Zhang, Z.-Y. et al. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. *Zhongxiyi Jiehe Xuebao* 6, 134-138 (2008).
369. Zhao F, Wang H, Kunda P, Chen X, Liu QL, Liu T. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71. *Oncol Rep.* 2013 Jun 28. doi: 10.3892/or.2013.2574. [Epub ahead of print]
370. Zhao, M., Xue, D.B., Zheng, B., Zhang, W.H., Pan, S.H. & Sun, B. Induction of apoptosis by artemisinin relieving the severity of inflammation in caerulein-induced acute pancreatitis. *World J Gastroenterol* 13, 5612-5617 (2007).
371. Zhao, X.-B., Liu, M.-X., Wu, K.-N. & Xing, T.-Y. Effects of artesunate and its mechanism on MCF-7 cells. *Zhongliu Fangzhi Yanjiu* 33, 745-747 (2006).
372. Zhao Y, Jiang W, Li B, Qi Yao Q, Dong J, Cen Y, Pan X, Li J, Zheng J, Pang X, Zhou H. Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G<sub>2</sub>/M phase *Int Immunopharmacol.* 11 (12):2039-2046 (2011).
373. Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W, Wan YY. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. *J Immunol.* 189(9):4417-4425, 2012.
374. Zheng, J.-S., Wang, M.-H., Huang, M., Luo, Y.-P. & Mi, C. Artesunate suppresses human endometrial carcinoma RL95-2 cell proliferation by inducing cell apoptosis. *Nanfang Yike Daxue Xuebao* 28, 2221-2223 (2008).
375. Zheng ZY, Wang JF, Hu ZP, Shen JP, Gao RL, Ye BD, Lin SY, Shen YP, Chen JF, Luo



- XS, Zhou YH, Yu RX. [Immune response of dendritic cells capturing antigens from apoptotic U937 cells induced by artesunate]. [Article in Chinese] *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 15(4):833-838 (2007)
376. Zheng GQ. Cytotoxic terpenoids and flavonoids from *Artemisia annua*. *Planta Med* 60, 54-57 (1994).
377. Zhou C, Pan W, Wang X, Chen T. Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. *J Cell Physiol*. 227(12):3778-3786 (2012).
378. Zhou, G.-B., Chen, S.-J., Wang, Z.-Y. & Chen, Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. *Cell Research* 17, 274-276 (2007).
379. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. *Vascul Pharmacol* 47, 131-138 (2007).
380. Zhou HJ, Wang Z, Li A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. *Anticancer Drugs*. 19(3):247-255 (2008).
381. Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. *Cancer Chemother Pharmacol*. 66, 21-29 (2010).
382. Zhou ZH, Chen FX, Xu WR, Qian H, Sun LQ, Lü XT, Chen L, Zhang J, Ji HC, Fei SJ. Enhancement effect of dihydroartemisinin on human  $\gamma\delta$  T cell proliferation and killing pancreatic cancer cells. *Int Immunopharmacol*. 2013 Oct 5. pii: S1567-5769(13)00360-3. doi: 10.1016/j.intimp.2013.09.015. [Epub ahead of print]
383. Zhu XX, Yang L, Li YJ, Zhang D, Chen Y, Kostecká P, Kmoníčková E, Zídek Z. Effects of sesquiterpene, flavonoid and coumarin types of compounds from *Artemisia annua* L. on production of mediators of angiogenesis. *Pharmacol Rep*. 65(2):410-420, 2013.
384. Zhu H, Liao SD, Shi JJ, Chang LL, Tong YG, Cao J, Fu YY, Chen XP, Ying MD, Yang B, He QJ, Lu JJ. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. *Free Radic Biol Med*. 2014 Mar 25. pii: S0891-5849(14)00143-9. doi: 10.1016/j.freeradbiomed.2014.03.026.
385. Zhu S, Liu W, Ke X, Li J, Hu R, Cui H, Song G. Artemisinin reduces cell proliferation and induces apoptosis in neuroblastoma. *Oncol Rep*. 2014 Jul 11. doi: 10.3892/or.2014.3323. [Epub ahead of print]
386. Zizak Z, Juranić Z, Opsenica D, Solaja BA. Mixed steroidal tetraoxanes induce apoptotic cell death in tumor cells. *Invest New Drugs*. 27(5):432-439 (2009).

### Artemisinin Pharmacology and Pharmacokinetics

1. Dhingra V, Rao KV, Narasu NL: Current status of artemisinin and its derivatives as antimalarial drugs. *Life Sci* 66:279-300, 2000.
2. Farombi EO, Adedara IA, Abolaji AO, Anamelechi JP, Sangodele JO. Sperm characteristics, antioxidant status and hormonal profile in rats treated with artemisinin. *Andrologia*. 2013 Sep 30. doi: 10.1111/and.12170. [Epub ahead of print]

3. Li Q, Si Y, Xie L, Zhang J, Weina P. Severe embryoletality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats. *Birth Defects Res B Dev Reprod Toxicol.* 86(5):385-393, 2009.
4. Li Y, Wu YL: An over four millennium story behind qinghaosu (artemisinin--a fantastic antimalarial drug from a traditional chinese herb). *Curr Med Chem* 10(21):2197-2230, 2003.
5. Medhi B, Patyar S, Rao RS, Byrav Ds P, Prakash A. Pharmacokinetic and Toxicological Profile of Artemisinin Compounds: An Update. *Pharmacology* 84(6):323-332, 2009.
6. Navaratnam V, Mansor SM, Sit NW, et al: Pharmacokinetics of artemisinin-type compounds. *Clin Pharmacokinet* 39:255-270, 2000.
7. Xing J, Bai KH, Liu T, Wang RL, Zhang LF, Zhang SQ. The multiple-dosing pharmacokinetics of artemether, artesunate, and their metabolite dihydroartemisinin in rats. *Xenobiotica.* 41(3):252-258, 2011.
8. Yin JY, Wang HM, Wang QJ, Dong YS, Han G, Guan YB, Zhao KY, Qu WS, Yuan Y, Gao XX, Jing SF, Ding RG. Subchronic toxicological study of two artemisinin derivatives in dogs. *PLoS One.* 2014 Apr 16;9(4):e94034. doi: 10.1371/journal.pone.0094034. eCollection 2014.